Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in polymyalgia rheumatica
NL-OMON45962Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Sarilumab plus shorter prednisone taper with Placebo plus longer prednisone taper (2 arms). Primary endpoint: Proportion of patients achieving sustained remission. Started Apr 2019; status: active, not recruiting.
02
Drugs
sarilumabprednisone
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON45962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45962.